CitiGroup Inc. (NYSE:C) Investors May Bypass Fed Efforts to Restrain Dividend Increase. CitiGroup Inc. (NYSE:C) was hoping to raise its annual dividend by $0.10 per share, as well as repurchase its stock, but was denied based upon the Comprehensive Capital Analysis and Review (CCAR). Citigroup Inc (NYSE:C) stock performance was -1.20% in last session and finished the day at $47.11. Traded volume was 33.01million shares in the last session and the average volume of the stock remained 30.30million shares. The beta of the stock remained 2.00. Citigroup Inc (NYSE:C) insider ownership is 0.10%.

Verizon Communications Inc. (NYSE:VZ), the largest U.S. wireless carrier and the one that gets the most revenue per customer, has been dragged into the fray. In the last week, with no formal announcement or fanfare, it matched AT&T’s latest price cut for big-spending, family-plan customers — itself a move to get closer to the $140 a month T-Mobile charges for an equivalent package. Verizon Communications Inc. (NYSE:VZ) dropped -0.17 percent to $48.04 Friday on volume of 20.78million shares. The intra-day range of the stock was $47.96 to $48.35. Verizon Communications Inc. (NYSE:VZ) has a market capitalization of $198.89billion.

General Motors Company (NYSE:GM) is set to add another 1,400 jobs at its Detroit-Hamtramck Assembly Plant, according to unnamed sources cited by The Detroit News. Corresponding with the announcement, which is expected to come April 8, is a scheduled Automotive Press Association event the Mayor of Detroit will attend. General Motors Company (NYSE:GM)’s stock on Apr 04, 2014 reported a decrease of -1.78% to the closing price of $34.81. Its fifty two weeks range is $27.11-$41.85. The total market capitalization recorded $55.34billion. The overall volume in the last trading session was 20.37million shares. In its share capital, GM has 1.59billion outstanding shares.

Gilead Sciences, Inc. (NASDAQ:GILD), research based pharmaceutical company, announced positive results for a pivotal study of its drug sofosbuvir for treatment of Japanese patients diagnosed with a common form of the hepatitis C virus. Gilead Sciences, Inc. (NASDAQ:GILD) had been in news for its drug Sovaldi in the U.S. in March when the country’s lawmakers had questioned the high costs of the drug. On Friday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) dropped -2.43% to close the day at $72.20. Company return on investment (ROI) is 18.70% and its monthly performance is recorded as -9.66%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is -2.85%.